Molecular Structure of Thalidomide (CAS NO.50-35-1):

IUPAC Name: 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Molecular Formula: C₁₃H₁₀N₂O₄
Molecular Weight: 258.229500 g/mol
H bond acceptors: 6
H bond donors: 1
#Freely Rotating Bonds: 1
Polar Surface Area: 74.76Ų
Index of Refraction: 1.646
Molar Refractivity: 62.35 cm³
Molar Volume: 171.7 cm³
Surface Tension: 69.9 dyne/cm
Enthalpy of Vaporization: 78.04 kJ/mol
Vapour Pressure: 1.65E-10 mmHg at 25°C
Density: 1.503 g/cm³
Melting Point: 269-271 °C
Boiling Point: 509.7 °C at 760 mmHg
Flash Point: 262.1 °C 
Water solubility: <0.1 g/100 mL at 22 °C
EINECS: 200-031-1
Categories: Intermediates & Fine Chemicals; Pharmaceuticals; API's; Cytokine signaling

 One source have suggested that  Thalidomide (CAS NO.50-35-1) had been developed under the direction of a Nazi scientist in 1944, other sources have suggested that it may have been first synthesised by British scientists at the University of Nottingham in 1949.

EPA Genetic Toxicology Program.

Safety Information of  Thalidomide (CAS NO.50-35-1):
Hazard Codes: T
Risk Statements: 46-61-21-25-62 
R46:May cause heritable genetic damage. 
R61:May cause harm to the unborn child. 
R21:Harmful in contact with skin. 
R25 :Toxic if swallowed. 
R62:Risk of impaired fertility.
Safety Statements: 53-22-26-36/37/39-45
S53:Avoid exposure - obtain special instructions before use. 
S22:Do not breathe dust. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: TI4375000
HazardClass: 6.1(b)
PackingGroup: III
Poison by ingestion. Moderately toxic by skin contact and intraperitoneal routes. Human teratogenic effects by ingestion: developmental abnormalities of the musculoskeletal and cardiovascular systems. Experimental reproductive effects. Questionable carcinogen with experimental tumorigenic and teratogenic data. Human mutation data reported. It was commonly used as a prescription drug in Europe in the late 1950s and early 1960s. Its use was discontinued because it was discovered to cause serious congenital abnormalities in the fetus, notably amelia and phocomelia (absence or deformity of the limbs, including hands and feet) when taken by a woman during early pregnancy. When heated to decomposition it emits toxic fumes of NO_x. Used as a sedative and hypnotic.

  Thalidomide , with CAS number of 50-35-1, can be called Phthalimide,N-(2,6-dioxo-3-piperidyl)- (6CI,7CI,8CI) ; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline ; 3-Phthalimidoglutarimide ; Contergan ; N-(2,6-Dioxo-3-piperidyl)phthalimide ; N-Phthaloylglutamimide ; a-(N-Phthalimido)glutarimide ; a-Phthalimidoglutarimide . It is a white powder. Thalidomide (CAS NO.50-35-1) is a sedative-hypnotic and multiple myeloma medication found to have an inhibitory effect on morning sickness,insomnia, coughs, colds and headaches, but it may lead to severe birth defects if it is taken during pregnancy.